LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 12

Search options

  1. Article ; Online: Reply to Letter to the Editor 'Weekly oxaliplatin and pre-operative radiotherapy as a new neoadjuvant therapy for locally advanced rectal cancer', by T. Watanabe et al. (Ann Oncol 2006; 17: 1173).

    Aschele, C / Friso, M L / Del Bianco, P / Pucciarelli, S

    Annals of oncology : official journal of the European Society for Medical Oncology

    2019  Volume 17, Issue 7, Page(s) 1173–1174

    Language English
    Publishing date 2019-12-10
    Publishing country England
    Document type Letter
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdj124
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer.

    Bertorelle, R / Briarava, M / Rampazzo, E / Biasini, L / Agostini, M / Maretto, I / Lonardi, S / Friso, M L / Mescoli, C / Zagonel, V / Nitti, D / De Rossi, A / Pucciarelli, S

    British journal of cancer

    2013  Volume 108, Issue 2, Page(s) 278–284

    Abstract: Background: Colorectal cancer (CRC) is an important cause of cancer-related death. Prediction of recurrence is an important issue in the treatment of disease, particularly for stage II patients. The level of telomere-specific reverse transcriptase ( ... ...

    Abstract Background: Colorectal cancer (CRC) is an important cause of cancer-related death. Prediction of recurrence is an important issue in the treatment of disease, particularly for stage II patients. The level of telomere-specific reverse transcriptase (hTERT), the catalytic component of the telomerase complex, increases along with CRC progression, but its prognostic value is still unclear.
    Methods: One hundred and thirty-seven CRC patients were studied for hTERT expression in tumour cells by real-time PCR. hTERT level was evaluated as a prognostic factor of overall survival (OS) in all patients and of disease recurrence in a subgroup of 50 stage II patients.
    Results: The median hTERT level was 93.8 copies (interquartile range 48-254). Patients with high hTERT levels (above the median) showed a significantly worse survival than those with low hTERT levels (below the median; log-rank test P<0.0001; hazard ratio (HR)=3.30 (95% confidence interval (CI) 1.98-5.52); P<0.0001). The negative prognostic value of high hTERT level is independent of the pathological stage and microsatellite instability (HR=2.09 (95% CI 1.20-3.64), P=0.009). Moreover, in stage II CRC, high hTERT levels identified patients with a higher risk of disease recurrence (HR=3.06 (95% CI 1.03-9.04), P=0.043) and death (HR=3.24 (95% CI 1.37-7.71), P=0.008).
    Conclusion: hTERT level is an independent prognostic marker of OS in CRC patients. In addition, assessment of hTERT level could improve stratification of stage II CRC patients for the risk of disease recurrence.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/metabolism ; Colorectal Neoplasms/diagnosis ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/mortality ; Disease Progression ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; RNA, Messenger/biosynthesis ; Telomerase/analysis ; Telomerase/genetics ; Telomerase/metabolism
    Chemical Substances Biomarkers, Tumor ; RNA, Messenger ; TERT protein, human (EC 2.7.7.49) ; Telomerase (EC 2.7.7.49)
    Language English
    Publishing date 2013-01-15
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/bjc.2012.602
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.

    Cecchin, E / Agostini, M / Pucciarelli, S / De Paoli, A / Canzonieri, V / Sigon, R / De Mattia, E / Friso, M L / Biason, P / Visentin, M / Nitti, D / Toffoli, G

    The pharmacogenomics journal

    2011  Volume 11, Issue 3, Page(s) 214–226

    Abstract: The aim of the study was the identification of a pharmacogenetic profile predictive of the tumor regression grade (TRG), considered as tumor response parameter, after neo-adjuvant treatment in rectal cancer patients. A total of 238 rectal cancer patients ...

    Abstract The aim of the study was the identification of a pharmacogenetic profile predictive of the tumor regression grade (TRG), considered as tumor response parameter, after neo-adjuvant treatment in rectal cancer patients. A total of 238 rectal cancer patients treated in a neo-adjuvant setting by a fluoropyrimidines-based chemo-radiotherapy (RT) were genotyped for 25 genetic polymorphisms in 16 genes relevant for treatment-associated pathways. Two polymorphisms were associated with TRG in a multivariate analysis: hOGG1-1245C > G, which can affect radiosensitivity and MTHFR-677C > T, which is involved in fluoropyrimidines action. Patients bearing at least one variant allele had a lower chance to get TRG ≤ 2 (OR = 0.46 95% CI 0.23-0.90, P = 0.024; and OR = 0.48 95% CI 0.24-0.96, P = 0.034; respectively). An association trend was observed for ABCB1-3435C > T, which is responsible for the multi-drug resistance (odds ratio (OR) = 1.96, 95% confidence interval (CI) 0.98-3.95, P = 0.057). Exploratory classification and regression tree (CART) analysis highlighted high-order gene-gene and gene-environment interactions and a genetic signature associated with differential response, with hOGG1-1245C > G as the most predictive factor. Other significant variables were: ABCB1-3435C > T, MTHFR-677C > T, ERCC1-8092C > A, ABCC2-1249G > A, XRCC1-28152G > A, XRCC3-4541A > G and patients gender. On the basis of CART results, patients were categorized into three groups according to tumor response probability: intermediate and high profiles had a higher probability to get TRG ≤ 2 as compared with low profiles (OR = 4.12 95% CI 1.46-11.65, P < 0.001 and OR = 12.44, 95% CI 5.52-28.04, P < 0.0001, respectively). This study evidences a major role of hOGG1-1245C > G and MTHFR-677C > T polymorphisms in the tumor response of rectal cancer patients treated with chemo-RT in neo-adjuvant setting, and shows the relevance of gene-gene and gene-environment interactions for complex phenotypes as tumor response.
    MeSH term(s) Adult ; Aged ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/therapeutic use ; Gene Expression Profiling ; Genetic Association Studies ; Genotype ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Polymorphism, Single Nucleotide/genetics ; Quinazolines/administration & dosage ; Quinazolines/therapeutic use ; Rectal Neoplasms/genetics ; Rectal Neoplasms/pathology ; Rectal Neoplasms/therapy ; Thiophenes/administration & dosage ; Thiophenes/therapeutic use ; Treatment Outcome
    Chemical Substances Quinazolines ; Thiophenes ; raltitrexed (FCB9EGG971) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2011-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2106831-8
    ISSN 1473-1150 ; 1470-269X
    ISSN (online) 1473-1150
    ISSN 1470-269X
    DOI 10.1038/tpj.2010.25
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.

    Urso, E / Serpentini, S / Pucciarelli, S / De Salvo, G L / Friso, M L / Fabris, G / Lonardi, S / Ferraro, B / Bruttocao, A / Aschele, C / Nitti, D

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

    2006  Volume 32, Issue 10, Page(s) 1201–1208

    Abstract: Aims: To investigate early and late complications in 44 patients with locally advanced mid-low rectal cancer enrolled in a phase I-II study, who had received an aggressive chemoradiation treatment (50.4Gy/28F; 5-FU continuous infusion and weekly ... ...

    Abstract Aims: To investigate early and late complications in 44 patients with locally advanced mid-low rectal cancer enrolled in a phase I-II study, who had received an aggressive chemoradiation treatment (50.4Gy/28F; 5-FU continuous infusion and weekly Oxaliplatin) followed by total mesorectal excision and 5-FU based postoperative chemotherapy. The aim of the present study is also to evaluate functional outcome and quality of life (QoL) in a sub-group of 22 patients.
    Methods: Standardized forms for early and late surgical complications were completed for all patients. Anorectal function and QoL were also investigated in 22 patients who underwent surgery in the same surgical unit, using the fecal incontinence scoring system (FIS) and EORTC-QLQ-CR38 questionnaires, compiled before and after radiotherapy and at least 8 months after surgery. The differences over time in scores were analyzed using repeated measure ANOVA.
    Results: The median age of patients (25 males and 19 females) was 58 (range: 34-73) years. A low anterior resection was performed in 39 cases, radical resection in 41, and 12 patients had a pathological complete response. There were no operative deaths; 4 and 9 patients required re-operation for early and late complications, respectively. FIS score did not present a significant worsening over time. According to data in the EORTC-QLQ-CR38 questionnaire, a significant improvement over time was found only for "future perspective".
    Conclusion: Our findings seem to indicate that this aggressive 5-FU-Oxalipaltin-based treatment implies no impairment of QoL and anorectal function, even if a high rate of late major complications was observed. Studies on larger series are required to confirm these results.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/radiotherapy ; Adenocarcinoma/surgery ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Fecal Incontinence/etiology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Postoperative Complications ; Quality of Life ; Rectal Neoplasms/drug therapy ; Rectal Neoplasms/radiotherapy ; Rectal Neoplasms/surgery ; Rectum/surgery ; Surveys and Questionnaires
    Chemical Substances Organoplatinum Compounds ; oxaliplatin (04ZR38536J) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2006-12
    Publishing country England
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study
    ZDB-ID 632519-1
    ISSN 0748-7983
    ISSN 0748-7983
    DOI 10.1016/j.ejso.2006.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Preoperative combined radiotherapy and chemotherapy for middle and lower rectal cancer: preliminary results.

    Pucciarelli, S / Friso, M L / Toppan, P / Fornasiero, A / Carnio, S / Marchiori, E / Lise, M

    Annals of surgical oncology

    2000  Volume 7, Issue 1, Page(s) 38–44

    Abstract: Background: Adjuvant treatment for rectal cancer is still controversial. This study reports on overall survival and disease-free survival, toxicity, downstaging, and surgical morbidity in rectal cancer patients who received combined chemoradiation ... ...

    Abstract Background: Adjuvant treatment for rectal cancer is still controversial. This study reports on overall survival and disease-free survival, toxicity, downstaging, and surgical morbidity in rectal cancer patients who received combined chemoradiation therapy followed by curative surgery.
    Methods: Between 1993 and 1998, 51 patients (31 males and 20 females; median age, 60 years; range, 33-73 years) underwent chemoradiation therapy followed by radical surgery for middle and lower rectal adenocarcinoma. Criteria for giving preoperative radiotherapy (total 45 Gy in 25 fractions of 1.8 Gy/day for 5 weeks) and chemotherapy (5-fluorouracil 350 mg/m2/day and leucovorin 10 mg/m2/day, bolus on days 1-5 and 29-33) were an age younger than 75 years; an Eastern Cooperative Oncology Group performance status score of 0 to 2; and clinical preoperative stage II-III. Forty-three low anterior and eight abdominoperineal resections were performed. Median follow-up time was 29 (range, 3-63) months.
    Results: Although grade 3 to 4 toxicity occurred in 14 cases (27.4%), all patients completed the planned adjuvant therapy. At pathology, a complete response was found in eight (15.7%) cases. Of the remaining 43 cases, 22 were stage I, 12 were stage II, and 9 were stage III. Five-year actuarial disease-free survival and overall survival rates were 86.4% and 85.5%, respectively. Whereas no local recurrences were found, 4 patients had distant metastases. Three patients died (1 of cancer-related causes), 45 are alive and disease free, and 3 are alive with disease.
    Conclusions: The combined preoperative chemoradiation approach used by us seems to improve the disease-free survival and overall survival of selected patients with rectal cancer. However, a longer follow-up time is required to confirm these preliminary results.
    MeSH term(s) Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adenocarcinoma/secondary ; Adenocarcinoma/therapy ; Adult ; Aged ; Anastomosis, Surgical/adverse effects ; Chemotherapy, Adjuvant ; Digestive System Surgical Procedures/adverse effects ; Disease-Free Survival ; Female ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Postoperative Care ; Preoperative Care ; Radiotherapy, Adjuvant ; Rectal Neoplasms/mortality ; Rectal Neoplasms/pathology ; Rectal Neoplasms/therapy ; Retrospective Studies ; Survival Rate
    Chemical Substances Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2000-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1007/s10434-000-0038-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.

    Aschele, C / Friso, M L / Pucciarelli, S / Lonardi, S / Sartor, L / Fabris, G / Urso, E D L / Del Bianco, P / Sotti, G / Lise, M / Monfardini, S

    Annals of oncology : official journal of the European Society for Medical Oncology

    2005  Volume 16, Issue 7, Page(s) 1140–1146

    Abstract: Background: Oxaliplatin (OXA) significantly enhanced the antitumour activity of 5-fluorouracil (FUra) in patients with advanced colorectal cancer and displayed radiosensitising properties in preclinical studies. This study was thus performed to test the ...

    Abstract Background: Oxaliplatin (OXA) significantly enhanced the antitumour activity of 5-fluorouracil (FUra) in patients with advanced colorectal cancer and displayed radiosensitising properties in preclinical studies. This study was thus performed to test the feasibility, identify the recommended doses (RDs) and explore preliminarily the clinical activity of weekly OXA and infused FUra combined with preoperative pelvic radiotherapy.
    Patients and methods: Forty-six patients with recurrent or locally advanced (cT3-4 and/or N+) adenocarcinomas of the mid-low rectum were treated with escalating doses of OXA (25, 35, 45, 60 mg/m2, weekly for 6 weeks) and FUra (200-225 mg/m2/day, 6-week infusion) concurrent to preoperative pelvic radiotherapy (50.4 Gy/28 fractions). The RDs for the phase II part of the study were immediately below the level resulting in dose-limiting toxicities in more than one third of the patients, or corresponded to the last planned dose level.
    Results: In the escalation phase, dose-limiting toxicities only occurred in one patient at the fourth level and one of six patients treated at the last planned dose level (grade III diarrhoea). OXA 60 mg/m2 and FUra 225 mg/m2/day are therefore the RDs for the regimen. Among 25 patients globally treated at these doses (phase II part), the incidence of grade III diarrhoea was 16% with no grade IV toxicity. Neurotoxicity did not exceed grade II (12%). All patients completed radiotherapy and were operated on as scheduled. Twenty-one of 25 patients had the tumour down-staged after chemoradiation with seven (28%) pathological complete responses and 12 (48%) residual tumours limited to ypT1-2N0.
    Conclusions: Weekly OXA, at doses potentially active systemically, can be combined with full-dose, infused FUra and radiotherapy. Given the low toxicity and promising activity, this regimen is being compared to standard FUra-based pelvic chemoradiation in a randomised study.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cohort Studies ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Preoperative Care ; Rectal Neoplasms/drug therapy ; Rectal Neoplasms/radiotherapy
    Chemical Substances Organoplatinum Compounds ; Oxaliplatin (04ZR38536J) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2005-05-13
    Publishing country England
    Document type Clinical Trial ; Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdi212
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.

    De Paoli, A / Chiara, S / Luppi, G / Friso, M L / Beretta, G D / Del Prete, S / Pasetto, L / Santantonio, M / Sarti, E / Mantello, G / Innocente, R / Frustaci, S / Corvò, R / Rosso, R

    Annals of oncology : official journal of the European Society for Medical Oncology

    2005  Volume 17, Issue 2, Page(s) 246–251

    Abstract: Background: The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT) in patients with locally advanced, resectable, rectal cancer.: Patients and methods: Fifty- ... ...

    Abstract Background: The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT) in patients with locally advanced, resectable, rectal cancer.
    Patients and methods: Fifty-three patients with potentially resectable T3, N0-2 (87%) and T4, N0-2 (13%) rectal cancer were treated with capecitabine (825 mg/m2, twice daily for 7 days/week) and concomitant RT (50.4 Gy/28 fractions). Patients underwent surgery after 6-8 weeks followed, upon physician's indications, by 4-months adjuvant capecitabine. The primary end point was to determine the rate of pathologic complete response. Secondary end points were to assess the rate of clinical response and the safety profile.
    Results: All patients but two completed the RT programme and 47 (89%) received 81%-100% of the capecitabine dose (100% of dose in 72% patients, 81%-95% in 17% patients and 48%-74% in 11% of patients). No patient had grade 4 toxicity. Grade 3 toxicity occurred in six patients (11%) and consisted mainly of leucopenia (4%) and hand-foot syndrome (4%). Mild or moderate toxicity was common and included leucopenia (72%), diarrhea (40%), proctitis (34%) and skin toxicity (20%). The overall clinical response rate was 58% and the downstaging rate was 57%, with a pathologic complete response rate of 24%. Among 34 patients with low-lying tumors (<or=5 cm from anal verge), 20 (59%) had a sphincter-saving operation.<br />Conclusions: Preoperative chemoradiation with capecitabine and RT appeared to be effective in locally advanced resectable, rectal cancer. The favorable safety profile of the combination might warrant the use of capecitabine and RT with other effective new drugs.
    MeSH term(s) Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use ; Capecitabine ; Combined Modality Therapy ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives ; Fluorouracil/therapeutic use ; Humans ; Male ; Middle Aged ; Patient Compliance ; Preoperative Care ; Rectal Neoplasms/drug therapy ; Rectal Neoplasms/radiotherapy ; Rectal Neoplasms/surgery
    Chemical Substances Antimetabolites, Antineoplastic ; Deoxycytidine (0W860991D6) ; Capecitabine (6804DJ8Z9U) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2005-11-09
    Publishing country England
    Document type Clinical Trial ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdj041
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Preoperative combined radiotherapy and chemotherapy for rectal cancer does not affect early postoperative morbidity and mortality in low anterior resection.

    Pucciarelli, S / Toppan, P / Friso, M L / Fornasiero, A / Vieceli, G / Marchiori, E / Lise, M

    Diseases of the colon and rectum

    1999  Volume 42, Issue 10, Page(s) 1276–83; discussion 1283–4

    Abstract: Purpose: It is not yet known whether preoperative combined radiotherapy and chemotherapy for rectal cancer affects postoperative mortality and morbidity. We therefore evaluated early postoperative complications in patients given adjuvant radiotherapy ... ...

    Abstract Purpose: It is not yet known whether preoperative combined radiotherapy and chemotherapy for rectal cancer affects postoperative mortality and morbidity. We therefore evaluated early postoperative complications in patients given adjuvant radiotherapy and chemotherapy before surgery for middle and lower rectal adenocarcinoma.
    Methods: Between 1994 and 1998, 41 patients underwent combined preoperative pelvic radiotherapy and chemotherapy at our institution. Most of the patients had 45 Gy (1.8 Gy/day/25 fractions) during five weeks plus 5-fluorouracil (350 mg/m2/day) and low-dose leucovorin (10 mg/m2/day) bolus on Days 1 to 5 and 29 to 33. Surgery was performed four to six weeks after completion of adjuvant therapy. The 41 patients (Group A) were retrospectively compared with 30 patients (Group B) who, in the same period, underwent surgery without preoperative adjuvant therapy. The groups were homogeneous for age, gender, preoperative risk factors, operating surgeon, and pathologic stage. Mean distance of the tumor from the anal verge was shorter in Group A patients (P = 0.031).
    Results: There were seven major postoperative complications in each group. No significant differences were found between the groups for morbidity and mortality rates. Considering all patients, more postoperative complications were found in patients scored as American Society of Anesthesiologists 3, in those with a preoperative hemoglobin value < 10 g/dl, and in those without a diverting stoma (P = 0.0048, P = 0.0453, and P = 0.0033, respectively). At multivariate analysis, independent predictors of major complications were American Society of Anesthesiologists score (relative risk, 343; P = 0.022), diverting stoma (relative risk, 159; P = 0.010), type of surgical procedure (relative risk, 38.9; P = 0.048), preoperative hemoglobin value (relative risk, 9.72; P = 0.061), and intraoperative blood loss (relative risk, 1; P = 0.027). In Group A patients, the absence of diverting stomas was associated with major postoperative complications (P = 0.0307), and independent predictors of major complications were American Society of Anesthesiologists score (relative risk, 56; P = 0.111) and absence of a diverting stoma (relative risk, 22.42; P = 0.222).
    Conclusion: Early postoperative complications after resection for middle and lower rectal adenocarcinoma are affected by intraoperative and preoperative risk factors and absence diverting stomas, but not by preoperative adjuvant therapy.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/mortality ; Adenocarcinoma/radiotherapy ; Adenocarcinoma/surgery ; Antimetabolites, Antineoplastic/therapeutic use ; Antineoplastic Agents/therapeutic use ; Carboplatin/therapeutic use ; Case-Control Studies ; Female ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Morbidity ; Multivariate Analysis ; Postoperative Complications/epidemiology ; Preoperative Care ; Radiotherapy, High-Energy ; Rectal Neoplasms/drug therapy ; Rectal Neoplasms/mortality ; Rectal Neoplasms/radiotherapy ; Rectal Neoplasms/surgery ; Retrospective Studies ; Risk Factors
    Chemical Substances Antimetabolites, Antineoplastic ; Antineoplastic Agents ; Carboplatin (BG3F62OND5) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 1999-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 212581-x
    ISSN 1530-0358 ; 0012-3706
    ISSN (online) 1530-0358
    ISSN 0012-3706
    DOI 10.1007/bf02234213
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Brachiterapia dei carcinomi della punta del naso. Una nuova tecnica.

    Rigon, A / Cauzzo, M C / Friso, M L / Zorat, P L / Zandonà, R

    La Radiologia medica

    1990  Volume 80, Issue 5, Page(s) 734–736

    Title translation Brachytherapy of carcinoma of the tip of the nose. A new technique.
    MeSH term(s) Brachytherapy/instrumentation ; Brachytherapy/methods ; Humans ; Nose Neoplasms/radiotherapy
    Language Italian
    Publishing date 1990-11
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 205751-7
    ISSN 1826-6983 ; 0033-8362
    ISSN (online) 1826-6983
    ISSN 0033-8362
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer.

    Esposito, G / Pucciarelli, S / Alaggio, R / Giacomelli, L / Marchiori, E / Iaderosa, G A / Friso, M L / Toppan, P / Chieco-Bianchi, L / Lise, M

    Annals of surgical oncology

    2001  Volume 8, Issue 4, Page(s) 311–318

    Abstract: Background: Our aim was to ascertain whether or not the response to preoperative chemoradiotherapy for rectal cancer is associated with p27kip1 and p53 protein expression.: Methods: Thirty-eight patients (27 male, 11 female) with a mean age of 59 ... ...

    Abstract Background: Our aim was to ascertain whether or not the response to preoperative chemoradiotherapy for rectal cancer is associated with p27kip1 and p53 protein expression.
    Methods: Thirty-eight patients (27 male, 11 female) with a mean age of 59 years (age range 33-87) and stage II-III rectal cancer received preoperative chemoradiotherapy (45-50.4 Gy; 5-FU 350 mg/m2/day and leucovorin 10 mg/m2/day). Thirty-one underwent low anterior resection; seven underwent abdominoperineal excision. Endoscopic tumor biopsies, performed before adjuvant therapy, were evaluated for: histologic type, tumor differentiation, mitotic index, and p27kip1 and p53 protein expression which were immunohistochemically determined. p53 expression was graded as: a) absent or present in < or =10% of tumor cells; b) present in 11-25%; c) present in 26-75%; and d) present in >75% of tumor cells. p27kip1 expression was assessed using both light microscopy (percent of stained cells x10 HPF) and cytometry with an image analysis workstation. Tumor response, ascertained with histology, was classified using a scale from 0 (no response) to 6 (complete pathologic response).
    Results: The mitotic index for the endoscopic biopsies was low in 14 cases, moderate in 17 cases, and high in 7 cases. p53 protein expression was found in 21 (a), 3 (b), 3 (c), and 11 (d) cases. The mean percentage of cells expressing the p27kip1 protein was 34 (range 0-77.14%). A close correlation was found between cytometric and light microscopy findings for p27kip1 (r2 = 0.92, P = .0001). Tumor differentiation was good in 5 cases, poor in 2 cases, and moderate in the remaining 31 cases. While the response to adjuvant therapy was good/complete in 25 (65.78%) cases, it was absent/poor in 13 (34.21%) cases. Univariate analysis associated type of adjuvant therapy (chemoradiotherapy, P = .0428) and p27kip1 protein lower expression (P = .0148) with a poor response to adjuvant treatment. Stepwise linear regression found overexpression of p53 and p27kip1 and young age to be independent variables that were linked to a good response to adjuvant therapy.
    Conclusions: Lack of p27kip1 and p53 protein expression in rectal cancer is associated with a poor response to preoperative adjuvant therapy.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/therapeutic use ; Cell Cycle Proteins/biosynthesis ; Combined Modality Therapy ; Cyclin-Dependent Kinase Inhibitor p27 ; Female ; Fluorouracil/administration & dosage ; Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Neoadjuvant Therapy ; Prognosis ; Rectal Neoplasms/drug therapy ; Rectal Neoplasms/genetics ; Rectal Neoplasms/radiotherapy ; Retrospective Studies ; Treatment Outcome ; Tumor Suppressor Protein p53/biosynthesis ; Tumor Suppressor Proteins
    Chemical Substances Antimetabolites, Antineoplastic ; Cell Cycle Proteins ; Tumor Suppressor Protein p53 ; Tumor Suppressor Proteins ; Cyclin-Dependent Kinase Inhibitor p27 (147604-94-2) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2001-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1007/s10434-001-0311-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top